Completed OBSERVATIONAL NCT00903721

Nasonex® Nasal Suspension 50 μg Long-term Designated Drug Use Investigation (Study P05876)

Nasonex® Nasal Suspension 50 μg Long-term Designated Drug Use Investigation

Sponsor: Organon and Co

Updated 8 times since 2017 Last updated: Feb 7, 2022 Started: Nov 30, 2008 Primary completion: Oct 31, 2012 Completion: Oct 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Allergic Rhinitis, this trial is completed. The trial is conducted by Organon and Co and has accumulated 8 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Mar 2022 — Jul 2024 [monthly]

Completed
Jan 2021 — Mar 2022 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed

▶ Show 3 earlier versions

Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None
Feb 2017 — Apr 2018 [monthly]

Completed NA
Jan 2017 — Feb 2017 [monthly]

Completed NA

First recorded

Nov 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Organon and Co

Data source: Organon and Co

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.